| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner
1 company
Slingsby Brian Taylor serves as a Director, 10% Owner at MLYS. Across recent SEC filings that breaks down to 2 buys and 2 sells. Those positions are worth an estimated $201.1M at current prices.
Historically, Slingsby Brian Taylor's trades have earned a below-average insider score of 48/100 across 4 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of +23.7%.
The biggest single holding is MLYS (~$201.1M) as Director, 10% Owner. The recent filings there lean toward selling, a net 1,040,741 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 20, 2025 | MLYS Mineralys Therapeutics, Inc. | Director, 10% Owner | Sell | 1,000,000 | $43.35 | $43,350,000.00 | -11.2% | -33.3% | - | |
| Mar 13, 2025 | MLYS Mineralys Therapeutics, Inc. | Director, 10% Owner | Buy | 259,259 | $13.50 | $3,499,996.50 | +3.0% | +15.2% | +94.0% | |
| Jul 24, 2024 | MLYS Mineralys Therapeutics, Inc. | Director, 10% Owner | Sell | 550,000 | $13.05 | $7,177,500.00 | -6.0% | +1.5% | +3.7% | |
| Feb 14, 2023 | MLYS Mineralys Therapeutics, Inc. | Director, 10% Owner | Buy | 250,000 | $16.00 | $4,000,000.00 | +2.8% | -10.1% | -19.3% |